For the first time in more than 10 years, idiopathic pulmonary fibrosis (IPF) care teams and patients will have a new treatment option following the Oct. 7 approval of Jascayd (nerandomilast) by the U.S. Food and Drug Administration (FDA). When I was diagnosed with IPF in January 2017,…
Jascayd is approved! So when can we start taking the IPF treatment?
When my husband, Donnie, started exhibiting concerning symptoms in early 2021, we initially attributed it to a lack of exercise during the pandemic or possibly long COVID-19. The initial shortness of breath he experienced seemed innocent enough, so he shrugged it off as a reminder that he probably needed to…
Long-term treatment with deupirfenidone (LYT-100) is generally well tolerated and may stabilize lung function in people with idiopathic pulmonary fibrosis (IPF), according to new clinical trial data announced by the therapy’s developer, Puretech Health. Puretech has already met with the U.S. Food and Drug Administration to discuss the…
Vaccines are a routine part of the pulmonary fibrosis (PF) journey, regardless of where you are along the path. However, recent changes in vaccine guidance from the U.S. Centers for Disease Control and Prevention (CDC) have caused some confusion. When I was diagnosed with idiopathic pulmonary…
The U.S. Food and Drug Administration (FDA) has approved nerandomilast, an oral medication developed by Boehringer Ingelheim, to treat adults with idiopathic pulmonary fibrosis (IPF) — when the lung disease has no known cause. The therapy will be marketed under the brand name Jascayd. According to a…
In just over a month, one of the largest gatherings of pulmonary fibrosis (PF) patients, caregivers, and health professionals will take place in Chicago, at the Pulmonary Fibrosis Foundation (PFF) Summit 2025. My idiopathic pulmonary fibrosis (IPF) diagnosis in January 2017 thrust my wife, Susan, and me…
Treatment with the experimental therapy nerandomilast appears to reduce the risk of death in people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), according to a new analysis of clinical trial data presented by the therapy’s developer, Boehringer Ingelheim. “The new pooled data zoom in on…
My journey to a diagnosis of idiopathic pulmonary fibrosis (IPF) began in the fall of 2016, when I was 59. It all started with a persistent cough. While the cough was annoying, especially to my wife, Susan, it wasn’t limiting my day-to-day activities. After seeing a radiologist’s report, my…
In 2009, I was at a point in my career in cardiology where I’d helped save many lives. I could spell both “pulmonary” and “fibrosis” because of some early transcription work I’d done, but I didn’t know much about pulmonary fibrosis (PF). I was quickly introduced to it when my…
LTI-03, an experimental treatment for idiopathic pulmonary fibrosis (IPF) that’s currently in clinical testing, was shown to reduce inflammation and scarring in experiments done on lung tissue collected from IPF patients, according to a study. The study showed that LTI-03’s effects on inflammation and scarring were similar to those…
